

*徐正龍醫師

所有發表期刊論文

1. [Hsieh SH](#), [Ying NW](#), [Wu MH](#), [Chiang WE](#), [Hsu CL](#), [Wong TY](#), [Jin YT](#), [Hong TM](#), [Chen YL](#). (2008) Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. *Oncogene* 27(26):3746-53.
2. [Chang KP](#), [Hsu CL](#), [Chang YL](#), [Tsang NM](#), [Chen CK](#), [Lee TJ](#), [Tsao KC](#), [Huang CG](#), [Chang YS](#), [Yu JS](#), [Hao SP](#). (2008) Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma. *Oral Oncol.* 2008 Aug;44(8):784-92.
3. [Cai Y](#), [Lee YF](#), [Li G](#), [Liu S](#), [Bao BY](#), [Huang J](#), [Hsu CL](#), [Chang C](#). (2008) A new prostate cancer therapeutic approach: Combination of androgen ablation with COX-2 inhibitor. *Int J Cancer.* 123(1):195-201
4. [Hsu CL*](#), [Ma WL](#), [Wu MH](#), [Wu CT](#), [Wu CC](#), [Lai JJ](#), [Jou YS](#), [Chen CW](#), [Yeh S](#), [Chang C](#). (2008) [Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma.](#) *Gastroenterology* 135(3):947-55, 955.e1-5_* (co-first author)
5. [Lin HY](#), [Yu IC](#), [Wang RS](#), [Chen YT](#), [Liu NC](#), [Altuwaijri S](#), [Hsu CL](#), [Ma WL](#), [Jokinen J](#), [Sparks JD](#), [Yeh S](#), [Chang C](#). (2008) Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. *Hepatology.* 47(6):1924-35.
6. [Chang KP](#), [Hao SP](#), [Chang JH](#), [Wu CC](#), [Tsang NM](#), [Lee YS](#), [Hsu CL](#), [Ueng SH](#), [Liu SC](#), [Liu YL](#), [Wei PC](#), [Liang Y](#), [Chang YS](#), [Yu JS](#). (2008) Macrophage inflammatory protein-3alpha is a novel serum marker for nasopharyngeal carcinoma detection and prediction of treatment outcomes. *Clin Cancer Res.* 14(21):6979-87.
7. [Ng SH](#), [Chan SC](#), [Yen TC](#), [Chang JT](#), [Liao CT](#), [Ko SF](#), [Liu FY](#), [Chin SC](#), [Fan KH](#), [Hsu CL](#). (2009) Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. *Eur J Nucl Med Mol Imaging.* 36(3):538.
8. [Wang X](#), [Ni J](#), [Hsu CL](#), [Johnykutty S](#), [Tang P](#), [Ho YS](#), [Lee CH](#), [Yeh S](#). (2009) Reduced Expression of Tocopherol-Associated Protein (TAP/Sec14L2) in Human Breast Cancer. *Cancer Invest.* 27(10):971-7.
9. [Fu JF](#), [Hsu CL](#), [Shih LY](#). MLL/AF10(OM-LZ) immortalized cells expressed cytokines and induced host cell proliferation in a mouse bone marrow transplantation model. (2010) *Int J Cancer.* 126(7):1621-9.
10. [M-H Wu](#), [W-L Ma](#), [C-L Hsu](#), [Y-L Chen](#), [J-H J Ou](#), [C K Ryan](#), [Y-C Hung](#), [S Yeh](#), and [C Chang](#). Androgen receptor promotes HBV-induced hepatocarcinogenesis through modulation of HBV RNA transcription. (2010) *Science Translational Medicine.* 19;2(32):32ra35.
11. [Yeh CT](#), [Chen HC](#), [Sung CM](#), [Hsu CL](#), [Lin CC](#), [Pan KT](#), [Tseng JH](#), [Hung CF](#). (2011) Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma. *BMC Cancer.* 2011 Mar 31;11:117.
12. [Chang KP](#), [Chang YT](#), [Wu CC](#), [Liu YL](#), [Chen MC](#), [Tsang NM](#), [Hsu CL](#), [Chang YS](#), [Yu JS](#). (2011) [Multiplexed immunobead-based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival.](#) *Head Neck.* 33(6):886-97.
13. [Lee LY](#), [Chang KP](#), [Hsu CL](#), [Chen TC](#), [Kuo TT](#). (2011) Small-Cell Neuroendocrine Carcinoma of the Nasopharynx: Report of a Rare Case

- Lacking Association With Epstein-Barr Virus. *Int J Surg Pathol.* 19(2):199-202.
14. Chang KP, Tsang NM, Liao CT, **Hsu CL**, Chung MJ, Lo CW, Chan SC, Ng SH, Wang HM, Yen TC. (2012) Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. *J Nucl Med.* 53(1):21-8.
 15. Ma WL, **Hsu CL***, Yeh CC, Wu MH, Huang CK, Jeng LB, Hung YC, Lin TY, Yeh S, Chang C. (2012) Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. *Hepatology.* 56(1):176-85
 16. **Hsu CL**, Chang KP, Lin CY, Chang HK, Wang CH, Lin TL, Liao CT, Tsang NM, Lee LY, Chan SC, Ng SH, Li HP, Chang YS, Wang HM. (2012) Plasma EBV DNA Concentration and Clearance Rate as Novel Prognostic Factors for Metastatic Nasopharyngeal Carcinoma. *Head & Neck* 34(8):1064-70
 17. Cheng NM, Chang JT, Huang CG, Tsan DL, Ng SH, Wang HM, Liao CT, Lin CY, **Hsu CL**, Yen TC. (2012) Prognostic value of pretreatment (18)F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma. *Eur J Nucl Med Mol Imaging.* 39(11):1673-84.
 18. Chan SC, Wang HM, Ng SH, **Hsu CL**, Lin YJ, Lin CY, Liao CT, Yen TC. (2012) Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients. *J Nucl Med.* 53(11):1730-5
 19. Chan SC, **Hsu CL***, Yen TC, Ng SH, Liao CT, Wang HM. (2013) The role of (18)F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. *Oral Oncol.* 49(1):71-8.
 20. **Hsu CL**, Chan SC, Chang KP, Lin TL, Lin CY, Hsieh CH, Huang SF, Tsang NM, Lee LY, Ng SH, Wang HM. (2013) Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. *Oral Oncol.* 49(6):620-5.
 21. Chan SC, Kuo WH, Wang HM, Chang JT, Lin CY, Ng SH, **Hsu CL**, Chang KP, Liao CT, Lin YJ, Yen TC. (2013) Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. *Ann Nucl Med.* (accepted)
 22. Hsu HC, Liu YS, Tseng KC, **Hsu CL**, Liang Y, Yang TS, Chen JS, Tang RP, Chen SJ, Chen HC. (2013) Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. *Int J Colorectal Dis.* (accepted)
 23. Fu JF, Yen TH, Chen Y, Huang YJ, **Hsu CL**, Liang DC, Shih LY. (2013) Involvement of Gpr125 in the myeloid sarcoma formation induced by cooperating MLL/AF10(OM-LZ) and oncogenic KRAS in a mouse bone marrow transplantation model. *Int J Cancer.* (accepted)